Cargando…

The Cost of Lost Productivity in an Opioid Utilizing Pain Sample

BACKGROUND AND AIMS: Chronic pain affects more adults in the United States than any other condition. Opioid medications are widely used in the treatment of chronic pain, but there remains considerable risk and cost associated with their use. This study aims to characterize the effects of opioid pres...

Descripción completa

Detalles Bibliográficos
Autores principales: Fishman, Michael A, Antony, Ajay B, Hunter, Corey W, Pope, Jason E, Staats, Peter S, Agarwal, Rahul, Connolly, Allison T, Dalal, Nirav, Deer, Timothy R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349546/
https://www.ncbi.nlm.nih.gov/pubmed/34377015
http://dx.doi.org/10.2147/JPR.S309691
_version_ 1783735585824833536
author Fishman, Michael A
Antony, Ajay B
Hunter, Corey W
Pope, Jason E
Staats, Peter S
Agarwal, Rahul
Connolly, Allison T
Dalal, Nirav
Deer, Timothy R
author_facet Fishman, Michael A
Antony, Ajay B
Hunter, Corey W
Pope, Jason E
Staats, Peter S
Agarwal, Rahul
Connolly, Allison T
Dalal, Nirav
Deer, Timothy R
author_sort Fishman, Michael A
collection PubMed
description BACKGROUND AND AIMS: Chronic pain affects more adults in the United States than any other condition. Opioid medications are widely used in the treatment of chronic pain, but there remains considerable risk and cost associated with their use. This study aims to characterize the effects of opioid prescribing for chronic pain and similar pain conditions on lost productivity in the United States. METHODS: This was a retrospective, longitudinal, observational study of chronic pain patients in 2011–2014. We identified patients with a diagnosis of musculoskeletal pain receiving index prescription for opioids in administrative claims and studied disability absence in a linked health and productivity management database. Patients were grouped as de novo and continued use opioid users before index, and by opioid dose in the year after index. Days of disability were compared before and after index with bootstrapping. Effect of opioid dose group on disability was evaluated with negative binomial regression. Lost productivity cost was compared before and after index. RESULTS: The cohort contained 16,273 de novo and 6604 continued use patients. On average, de novo patients used 24.8 days of disability after index, an increase of 18.3 more days compared to before (p < 0.001). Continued use patients used 30.7 days after index, 9 more days than before (p < 0.001). There was a dose–response relationship between dose group and days of disability in de novo patients (p < 0.001). The weighted-average cost per person of lost productivity was $4344 higher in the year after index compared to the year before. CONCLUSION: Opioid prescriptions for pain patients were associated with significant disability use and lost productivity costs. With the evolution of opioid-prescribing practices, CDC recommendations, and the HHS Pain Management Best Practices, there is opportunity to use alternative pain therapies without the risks of opioid-induced side effects to improve work productivity.
format Online
Article
Text
id pubmed-8349546
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-83495462021-08-09 The Cost of Lost Productivity in an Opioid Utilizing Pain Sample Fishman, Michael A Antony, Ajay B Hunter, Corey W Pope, Jason E Staats, Peter S Agarwal, Rahul Connolly, Allison T Dalal, Nirav Deer, Timothy R J Pain Res Original Research BACKGROUND AND AIMS: Chronic pain affects more adults in the United States than any other condition. Opioid medications are widely used in the treatment of chronic pain, but there remains considerable risk and cost associated with their use. This study aims to characterize the effects of opioid prescribing for chronic pain and similar pain conditions on lost productivity in the United States. METHODS: This was a retrospective, longitudinal, observational study of chronic pain patients in 2011–2014. We identified patients with a diagnosis of musculoskeletal pain receiving index prescription for opioids in administrative claims and studied disability absence in a linked health and productivity management database. Patients were grouped as de novo and continued use opioid users before index, and by opioid dose in the year after index. Days of disability were compared before and after index with bootstrapping. Effect of opioid dose group on disability was evaluated with negative binomial regression. Lost productivity cost was compared before and after index. RESULTS: The cohort contained 16,273 de novo and 6604 continued use patients. On average, de novo patients used 24.8 days of disability after index, an increase of 18.3 more days compared to before (p < 0.001). Continued use patients used 30.7 days after index, 9 more days than before (p < 0.001). There was a dose–response relationship between dose group and days of disability in de novo patients (p < 0.001). The weighted-average cost per person of lost productivity was $4344 higher in the year after index compared to the year before. CONCLUSION: Opioid prescriptions for pain patients were associated with significant disability use and lost productivity costs. With the evolution of opioid-prescribing practices, CDC recommendations, and the HHS Pain Management Best Practices, there is opportunity to use alternative pain therapies without the risks of opioid-induced side effects to improve work productivity. Dove 2021-08-04 /pmc/articles/PMC8349546/ /pubmed/34377015 http://dx.doi.org/10.2147/JPR.S309691 Text en © 2021 Fishman et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Fishman, Michael A
Antony, Ajay B
Hunter, Corey W
Pope, Jason E
Staats, Peter S
Agarwal, Rahul
Connolly, Allison T
Dalal, Nirav
Deer, Timothy R
The Cost of Lost Productivity in an Opioid Utilizing Pain Sample
title The Cost of Lost Productivity in an Opioid Utilizing Pain Sample
title_full The Cost of Lost Productivity in an Opioid Utilizing Pain Sample
title_fullStr The Cost of Lost Productivity in an Opioid Utilizing Pain Sample
title_full_unstemmed The Cost of Lost Productivity in an Opioid Utilizing Pain Sample
title_short The Cost of Lost Productivity in an Opioid Utilizing Pain Sample
title_sort cost of lost productivity in an opioid utilizing pain sample
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349546/
https://www.ncbi.nlm.nih.gov/pubmed/34377015
http://dx.doi.org/10.2147/JPR.S309691
work_keys_str_mv AT fishmanmichaela thecostoflostproductivityinanopioidutilizingpainsample
AT antonyajayb thecostoflostproductivityinanopioidutilizingpainsample
AT huntercoreyw thecostoflostproductivityinanopioidutilizingpainsample
AT popejasone thecostoflostproductivityinanopioidutilizingpainsample
AT staatspeters thecostoflostproductivityinanopioidutilizingpainsample
AT agarwalrahul thecostoflostproductivityinanopioidutilizingpainsample
AT connollyallisont thecostoflostproductivityinanopioidutilizingpainsample
AT dalalnirav thecostoflostproductivityinanopioidutilizingpainsample
AT deertimothyr thecostoflostproductivityinanopioidutilizingpainsample
AT fishmanmichaela costoflostproductivityinanopioidutilizingpainsample
AT antonyajayb costoflostproductivityinanopioidutilizingpainsample
AT huntercoreyw costoflostproductivityinanopioidutilizingpainsample
AT popejasone costoflostproductivityinanopioidutilizingpainsample
AT staatspeters costoflostproductivityinanopioidutilizingpainsample
AT agarwalrahul costoflostproductivityinanopioidutilizingpainsample
AT connollyallisont costoflostproductivityinanopioidutilizingpainsample
AT dalalnirav costoflostproductivityinanopioidutilizingpainsample
AT deertimothyr costoflostproductivityinanopioidutilizingpainsample